---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-021304"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T00:17:42.841269+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# X4 Pharma Q1 net income $0.3M on $28.8M revenue; XOLREMDI sales $3.5M since launch; 4WARD trial on track

## Summary
- Q1 net income $0.3M vs loss $51.8M YoY; revenue $28.8M included $27.9M license fee from Norgine.
- XOLREMDI cumulative U.S. net sales $3.5M since May 2024 launch through March 2025.
- Phase 3 4WARD CN trial full enrollment expected 3Q/4Q 2025; top-line data in 2H 2026.
- Strategic restructuring to cut annual spending by $30-35M; cash $87.7M funds ops into 1H 2026.
- Completed 1-for-30 reverse stock split effective April 28, 2025; shares reduced from ~173.6M to ~5.8M.

## SEC filing metadata
- accession: 0001628280-25-021304
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000162828025021304/0001628280-25-021304-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000162828025021304/xfor-20250501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-021304
- JSON: https://secwatch.observer/filing/0001628280-25-021304.json
- Plain text: https://secwatch.observer/filing/0001628280-25-021304.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.